---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076595"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:40:15.414416+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline

## Summary
- Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).
- Q4 net income $43.7M ($0.25/sh) vs $7.7M ($0.04/sh) a year ago; Adj. EBITDA $84.2M.
- FY2025 net product revenue $563.0M (+17% YoY); net income $37.0M vs $0.9M in FY2024.
- FY2026 total net revenue guidance $350M - $420M, a 25% to 38% decline from FY2025; expects Q1 drop then sequential growth.
- Cash and equivalents $94.3M with no outstanding debt as of Dec 31, 2025.

## SEC filing metadata
- accession: 0001193125-26-076595
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000119312526076595/0001193125-26-076595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000119312526076595/orgo-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076595
- JSON: https://secwatch.observer/filing/0001193125-26-076595.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.